Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behcet's disease without formation of antidrug antibodies

DM Verboom; Tim van der Houwen; JH Kappen; Paul van Daele; Wim Dik; Marco Schreurs; P.M. van Hagen; Jan van Laar

Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behcet's disease without formation of antidrug antibodies

DM Verboom, Tim van der Houwen, JH Kappen, Paul van Daele, Wim Dik, Marco Schreurs, P.M. van Hagen, Jan van Laar

Research output: Contribution to journal › Article › Academic › peer-review

5 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	43-47
Number of pages	5
Journal	Clinical & Experimental Rheumatology
Volume	37
Issue number	6
Publication status	Published - 2019

Cite this

@article{bdbe7a244a504919b4ac4959f828d37f,

title = "Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behcet's disease without formation of antidrug antibodies",

author = "DM Verboom and {van der Houwen}, Tim and JH Kappen and {van Daele}, Paul and Wim Dik and Marco Schreurs and {van Hagen}, P.M. and {van Laar}, Jan",

year = "2019",

language = "Undefined/Unknown",

volume = "37",

pages = "43--47",

journal = "Clinical & Experimental Rheumatology",

issn = "0392-856X",

publisher = "Clinical and Experimental Rheumatology S.A.S.",

number = "6",

}

TY - JOUR

T1 - Adalimumab provides long-lasting clinical improvement in refractory mucocutaneous Behcet's disease without formation of antidrug antibodies

AU - Verboom, DM

AU - van der Houwen, Tim

AU - Kappen, JH

AU - van Daele, Paul

AU - Dik, Wim

AU - Schreurs, Marco

AU - van Hagen, P.M.

AU - van Laar, Jan

PY - 2019

Y1 - 2019

M3 - Article

SN - 0392-856X

VL - 37

SP - 43

EP - 47

JO - Clinical & Experimental Rheumatology

JF - Clinical & Experimental Rheumatology

IS - 6

ER -